Innate immunity (natural resistance) is recognized as the first echelon in the battle against 'microbial terror'. Microbial recognition is a complex process that depends on the integrity of the complement system and requires specialized receptors on natural killer cells and nucleotide-binding oligomerization domain (NOD) proteins [1] .
Introduction
Innate immunity (natural resistance) is recognized as the first echelon in the battle against 'microbial terror'. Microbial recognition is a complex process that depends on the integrity of the complement system and requires specialized receptors on natural killer cells and nucleotide-binding oligomerization domain (NOD) proteins [1] .
An important role in innate immunity has been recently ascribed to the Toll-like receptor (TLR) family. TLRs were first identified in Drosophila as receptors that mediate protection against fungal infections [2, 3] . TLRs are surprisingly of very limited heterogeneity [4] but they have potent capacity to sense micro-organisms and alert body defense system about the presence of infectious danger. This is achieved through recognition of conserved microbial patterns such as unmethylated CpG motifs in bacterial DNA [5] , singlestranded or double-stranded (ds) viral RNA, lipopolysaccharide, peptidoglycan, and bacterial flagellin (for review, see [6] ). However, the role of TLRs extends beyond microbial recognition because recent evidence places them at the interface between innate and adaptive immunity [7] . This function is accomplished through coordinated upregulation of major histocompatibility complex class II and costimulatory molecules (e.g. CD40 and B7 family), resulting in much more efficient antigen presentation [8] . Furthermore, TLR-induced secretion of type I IFNs IL-6, tumor necrosis factor-α, and IL-12 directs maturation and sublineage commitment of immune cells that participate in the adaptive immune response [9, 10] . For example, type I IFNs augment antigen-specific CD4 + and CD8 + T cell responses and, in an autocrine manner, upregulate costimulatory molecule expression on dendritic cells [11] [12] [13] [14] . When combined with IL-12, type I IFNs increase natural killer cell mediated cytotoxicity and, together with IL-6, they drive B cell differentiation and immunoglobulin secretion [15] [16] [17] [18] [19] .
In this review we discuss recent evidence that suggests a role for TLRs in the pathogenesis of systemic autoimmunity. microbial products may induce autoimmunity by triggering the bystander activation of the immune system, which, if not regulated, can break the anergic state, leading to the expansion of dormant autoreactive clones.
Because the innate response to microbial products primarily depends on TLRs, it is not surprising that recent studies have implicated these receptors in the pathogenesis of autoimmunity, particularly TLR3, -7, -8, and -9 [21] [22] [23] [24] [25] [26] [27] [28] . In contrast to other TLRs, which are primarily localized at the outer cell membrane, this subgroup of TLRs is localized intracellularly. Even more importantly, these TLRs recognize nucleic acid motifs or their synthetic analogs (e.g. ds or single-stranded viral or host RNA [TLR3 and TLR7/8] or hypomethylated bacterial CpG-DNA [TLR9]). Macromolecular complexes of RNA or DNA associated with proteins, such as in chromatin, Ku autoantigen, topoisomerase, Sm/snRNP complexes, ribosomes, or in Ro/La (SS-A/SS-B) antigens, are well known targets of autoimmunity in systemic autoimmune diseases (mixed connective tissue disease, systemic lupus erythematosus [SLE], Sjögren's syndrome, and scleroderma) [29] [30] [31] [32] [33] [34] [35] . Another distinctive feature of this subfamily of TLRs is that, in humans, TLR7/8 and TLR9 exhibit a very limited cellular distribution and are detectable only in B cells and plasmacytoid dendritic cells (pDCs) [36] . In mice, in addition to B cells and pDCs, myeloid dendritic cells and macrophages also express TLR7 and TLR9 receptors and can respond to poly I:C -a synthetic ligand for TLR3 [37] . Mouse B cells, but not human B cells, also proliferate and differentiate into antibody-secreting cells when stimulated with lipopolysaccharide. This requires full assembly of the multireceptor signaling complex containing TLR4 and other accessory molecules (for review, see [2, 7] ).
The question remains regarding whether TLR activation can bypass tolerance and induce autoimmunity, such that autoimmunity is a natural and recurring consequence of systemic infection. Before attempting to answer this question, one must distinguish between normal transient low-affinity autoimmune responses and self-destructive autoimmune diseases. In a normal individual short exposure to microbial products will induce only a transient activation of TLRexpressing cells, including low-affinity self-reactive B cell clones and pDCs, because these cells are under tight regulation by SOCS (suppressors of cytokine stimulation) proteins [38] and regulatory cytokines [39] [40] [41] . However, one can postulate a number a ways in which this normal lowaffinity autoimmune response could progress to autoimmune disease, given the right circumstances or host factors. For example, one might suspect that TLR expression or its subcellular distribution is abnormal in mouse strains with autoimmune diseases. Whereas a loss-of-function mutation in TLR results in increased susceptibility to infections [42] , at the opposite end of the spectrum, productive mutations in TLR might result in increased receptor avidity for otherwise low-affinity foreign or even unrelated self TLR ligands. Another possibility is that the inducibility or the function of SOCS proteins may be inadequate in autoimmune cells. Finally, the endogenous supply of self TLR ligands may be increased either because of the abnormal apoptotic cell death or because of the inefficient clearance of apoptotic material.
What all these possibilities have in common is the paradigm that TLR can respond to endogenous ligands (e.g. to self-DNA, heat shock proteins, minimally oxidized low density lipoprotein, and saturated fatty acids, to name but a few) [28, 43, 44] (for review, see [45] ). Alternatively, presumed endogenous TLR ligands might need to undergo some type of modification before they can gain the capacity to stimulate TLRs. With respect to chromatin complexes, aberrant DNA methylation, oxidative DNA damage, differential cleavage of DNA, and histone phosphorylation are just a few modifications that may result in increased TLR stimulation and 'adjuvanticity'.
Toll-like receptors and interferons in lupus
Although at this time we cannot confirm or rule out any of the above possibilities, we know that some of the downstream events that follow TLR activation (e.g. type I and type II IFN secretion) play a well established role in the pathogenesis of systemic autoimmunity [19, 46, 47] . IFN-γ has long been considered the core cytokine in the pathogenesis of SLE [47] . Even more abundant evidence supports a role for type I IFNs. For example, similarly to IFN-γ, type I IFNs can promote isotype switching to T-helper-1-like isotypes (IgG 2a , IgG 2b , and IgG 3 in mice) that are capable of activating the complement system [48] . This may explain the predominance of these isotypes in animal models of lupus and the well known contribution of complement-mediated activation to the tissue injury in lupus. Increased concentrations of IFN-α correlate directly with disease activity and severity in human SLE [49] [50] [51] [52] , and there are well documented case reports of patients who developed SLE-like clinical manifestations after treatment with IFN-α [53, 54] . Furthermore, IFN genetic signatures are found in SLE patients [55, 56] . Moreover, IFN-α in sera of lupus patients mediated differentiation of monocytes into potent antigen-presenting cells [13] , whereas DNAse-sensitive immune complexes stimulated the FcγR-dependent production of IFN-α by pDCs [57] . A similar requirement for FcγR and TLR9 was seen in murine myeloid dendritic cells stimulated with chromatin immune complexes [58] . Finally, in vivo treatment of NZB mice with type A(D) CpG oligodeoxynucleotides (ODNs) induced abnormally high serum levels of IFN-α [59] .
Where is this IFN-α coming from? Accumulating evidence suggests that pDCs (also known as natural IFN-α-producing cells) are the major, but not exclusive, producers of type I IFNs following infections with DNA viruses (e.g. mouse cytomegalovirus, herpes simplex viruses types 2 and 1) [60, 61] , and following stimulation with certain types of CpG-ODNs (types A and C [62, 63] ). In all of these instances, IFN-α production required TLR9. However, even though the above evidence suggests a primary role for TLR9, this is not the exclusive innate receptor that can trigger high IFN-α production in lupus mice. Indeed, in a study conducted almost 4 decades ago, injection of poly I:C into NZB/W F 1 mice accelerated lupus nephritis [64] . Poly I:C closely resembles dsRNA viruses and requires a TLR3 receptor in order to induce high IFN-α secretion. A recent study conducted by Braun and coworkers [65] provided additional evidence that poly I:C can aggravate renal disease in B6 lpr mice, simultaneously causing polyclonal B cell activation and autoantibody secretion. In concordance with these results, NZB mice lacking the α-chain of the IFN-α/β receptor produced fewer autoantibodies and exhibited reduced renal pathology. More importantly, these mice survived longer [66] . Similar results were observed in B6 lpr mice, in which type I IFNs appeared to be responsible for both lymphoproliferation and for immune complex deposition in kidneys [65] . However, opposing results were observed in a recent study by Hron and Peng [67] , in which MRL-Fas lpr/lpr mice lacking IFN receptor 1 exhibited worsened lymphoproliferation, autoantibody production and end-organ disease, suggesting that type I IFNs may play a protective role, at least in some animal models of autoimmunity.
Curiously, immature pDCs and human B cells do not express TLR3 [36] . A recent study by Pawar and coworkers [68] showed that treatment with the TLR7/8 agonist R-848 worsened immune complex glomerulonephritis in MRLFas lpr/lpr lupus mice, but it remains to be determined whether such effect required type I IFN.
Diversity of Toll-like receptor 9 ligands and their role in the pathogenesis of lupus
TLR9 is a receptor for microbial CpG-DNA [5, 69] . It recognizes a single-stranded 'CpG motif', consisting of unmethylated CpG dinucleotides flanked by particular bases [70, 71] . The GACGTT hexamer is the most stimulatory CpG motif in rodents, whereas GTCGTT motif works best in primates. However, recent studies have identified additional requirements for optimal TLR9 stimulation (e.g. the need for the 5′ T and additional bases 3′ to the CpG hexamer) [72] [73] [74] . Stimulation with bacterial CpG-DNA can be mimicked both in vitro and in vivo with synthetic CpG-ODNs. Based on cell type preferences and the ability to form duplexes or complex structures, CpG-ODNs can be divided into three major types. Type A(D) CpG-ODNs contain poly-G rich tails and a central palindromic CpG sequence with the natural phosphodiester (PO) backbone. These ODNs easily form secondary structures (e.g. G4 strands), or even larger aggregates [75] , and preferentially stimulate pDCs in humans and in mice [62, 63] . Type B(K) CpG-ODNs have linear nonpalindromic CpG-ODN sequences, and are typically made with the nuclease-resistant phosphorothioate (PS) backbone. These ODNs are very good stimulators of both human and mouse B cells [62, 63, 71] . Finally, type C CpGODNs contain a 5′ TCG motif and CpG-containing palindromes, allowing them to form secondary structures. These ODNs stimulate both B cells and pDCs in the human system. Interestingly, the length of the palindrome correlates well with the ability of these ODNs to activate pDCs but not B cells [76] [77] [78] .
Even though stimulation with microbial CpG-DNA can induce anti-dsDNA antibodies in animal models of lupus [79, 80] , and TLR9-deficient lupus mice fail to produce anti-chromatin (dsDNA) antibodies [81] , it is still difficult to establish a direct link between exposure to microbial CpG-DNA and induction of lupus. Rather, microbial DNA may be involved in triggering lupus flares. Endogenous retroviruses were once considered to be etiologic factors in lupus, but strong evidence supporting this possibility is lacking [82] . Interestingly, some mainly circumstantial evidence suggests a role for chronic Epstein-Barr virus infection in the pathogenesis of SLE [83] . However, instead of considering lupus a model for the 'chronic silent infection', one must seek alternative (endogenous) ligands for the TLR9. Clearly, the prime candidate would be mammalian DNA itself. Indeed, unbound and immune-complexed host dsDNA was identified in lupus sera several decades ago [84] . However, in contrast to bacterial DNA, freshly purified unmodified mammalian DNA is not immune stimulatory. There are several possible explanations for this [85] [86] or in several other regions of the mammalian genome (e.g. immunoglobulin switch regions). These motifs can block TLR9-induced activation in both a cis and trans manner.
Surprisingly, chromatin-containing immune complexes in lupus sera were capable of inducing proliferation of rheumatoid factor-specific B cells (AM14-transgenic B cells) and DNA-specific B cells (3H9-transgenic B cells) [24, 87] . This proliferation was sensitive to treatment with DNAse and required unmethylated CpG sequences. It also required a synergy between the TLR9/MyD88 pathway and B cell receptor for antigen (BCR)-mediated signaling. For example, blocking the calcineurin pathway with cyclosporine A diminished BCR-dependent proliferation, whereas treatment with either inhibitory ODNs or chloroquine blocked TLR9-mediated signaling. Although CpG-DNA fails to induce extracellular signal-regulated kinase (ERK) phosphorylation in B cells, immune complexes containing chromatin were capable of inducing ERK activation in B cells. They also stimulated IFN-α production by pDCs [58] .
Taken together these data suggest that circulating DNA in lupus sera is either enriched in immunostimulatory CpG sequences, or is epigenetically modified to ensure more avid interaction between the DNA and TLR9. Indeed, DNA isolated from serum immune complexes in lupus contains disproportionably more guanosine/cytosine nucleotides than adenine/thymine residues [88] . Some data suggest that such circulating DNA may be derived from activated T cells [89, 90] . CpG islands [91] 
Toll-like receptor 9, B cell ontogeny, and the innate model of lupus
During ontogeny, B cells progress through several developmental stages, during which they appear extremely sensitive to microenvironmental influences and/or self-antigens, resulting in either positive or negative selection of B cells [95] [96] [97] . A negative selection of B cells, similarly to T cells, depends on the overall affinity of clonotypic BCR for the self-antigen. Immature B cells are enriched in self-reactive specificities, including those against DNA, and are particularly vulnerable to strong BCR signals [98] . The encounter with self-BCR ligands will typically result in clonal deletion, but a few clones may be rescued by receptor editing or by clonal anergy. A question is whether exposure to self-TLR ligands during development can rescue potentially self-reactive clones from negative selection. Under normal circumstances, the balance between the inhibitory DNA motifs and stimulatory CpG sequences in self-DNA will probably favor apoptosis in immature B cells specific for self-DNA, because the TLR9-mediated cosignal will not be generated. Although singlestranded CpG-ODNs can rescue immature non-DNA-reactive WEHI-231 cells from BCR-induced apoptotic cell death [99] , similar studies performed with natural TLR9 ligands (e.g. with ds bacterial DNA) suggest the opposite (Lenert P, unpublished data). However, anti-DNA specificity of at least some B cells in 3H9 mice transgenic for the heavy chain of an anti-DNA antibody [100] suggests that exposure to self-DNA may not always result in clonal deletion, and that some DNA-specific clones may escape tolerance.
The next question is toward which differentiation pathway will surviving self-reactive B cell clones be directed -MZ/B1-B pathway or follicular B cell pathway? Some studies suggest that low-affinity autoreactive B cells will likely be diverted toward the MZ-B cell pathway [101] [102] [103] [104] [105] [106] . However, despite the block in MZ-B cell development, male BXSB mice develop a systemic autoimmune disease, suggesting that under some conditions low-affinity autoreactive B cells may be redirected toward the follicular B cell pathway [107] . [112] , which are capable of undergoing isotype switching [113] .
The existence of low-affinity anti-DNA or rheumatoid factor producing B cell clones within the MZ-B cell compartment may be beneficial because these antibodies induce more efficient removal of cellular debris by phagocytes. Transient appearance of low affinity anti-single-stranded or dsDNA antibodies, preferentially of IgM and IgG 3 isotypes, will probably accompany any systemic exposure to bacteria. At the same time, MZ-B cell derived IL-10 secretion may be important for downregulating the endotoxin-induced inflammatory cytokine storm that characterizes early stages of bacterial sepsis. In addition, IL-10 may also finely modulate the activity of antigen-presenting cells, including pDCs, for example by suppressing the IFN-α production.
In normal circumstances the TLR9-mediated (and TLR7-mediated) activation of splenic autoreactive B cells will be self-limiting and will probably cause only minimal tissue damage. We propose a different scenario in the pathogenesis of lupus (Fig. 1) . Although exogenous TLR9 (and TLR7) ligands (such as microbial DNA) may trigger lupus flares through formation of phlogogenic CpG-DNA (or RNP)/ anti-DNA (anti-RNP) immune complexes and simultaneous activation of pDCs [19] , it is the continuous (or repetitive) exposure to modified self-CpG-DNA that probably drives the survival and expansion of self-DNA-reactive B cell clones. Exposure to self-hypomethylated DNA will induce secretion of low-affinity anti-DNA antibodies initially. [93] . They can also stimulate IFN-α secretion from human pDCs [114] .
Exposure to ultraviolet light and hormonal (estrogenic) influences may further increase the availability of self-TLR ligands, generating the characteristic lupus autoantibody profile [115] . Not surprisingly, inappropriate release of self-DNA from damaged tissues, such as skin, has long been suspected to underlie SLE pathogenesis [84] . Nucleosomes released from apoptotic cells in lupus are somehow enriched in self-TLR9-binding DNA sequences, possibly related to decreased DNA methyltransferase activity [89] secondary to cellular activation [116] . Interestingly, medications that can cause drug-induced lupus (e.g. hydralazine and procainamide) are capable of blocking methyltransferase activity [117] , and some stimulatory effects of DNA may not require TLR9 receptor at all, as recently noticed in TLR9-deficient cells [118] . Thus, although MZ-B cells may play a crucial role in the initiation of animal lupus, it is the interaction between autoreactive T cells and IFN-primed follicular B cells that is critically important for the amplification of the autoimmune circuit, generating high affinity complement-fixing autoantibodies. Therefore, attempts to block CD40L/CD40 or CD28/B7 interactions, or type I IFNs may be promising therapeutic options for lupus.
Targeting Toll-like receptor activation of autoreactive B cells and plasmacytoid dendritic cells with inhibitory DNA sequences
Halpern and Pisetsky made the original observation that certain poly-G ODNs containing the nuclease-resistant PS backbone, but not those synthesized with the PO backbone, could block the production of IFN-γ induced by mitogens (concanavalin A), bacterial DNA, or PMA/ionomycin. In macrophages, these ODNs also blocked IL-12 secretion induced by bacterial DNA [119, 120] . However, these effects occurred at high micromolar concentrations and were not specific for the TLR9 pathway [121] .
Several years later, while studying the role of CpG motifs in the immunogenicity of adenoviral vectors, Krieg and coworkers [122] discovered that certain CpG motifs, particularly those preceded by C and followed by G (e.g. the CCGG motif), were not only nonstimulatory but also could specifically block CpG-induced immune activation. It was subsequently shown that methylated CpG motifs in mammalian DNA, and ODNs containing GC flips were also capable of suppressing bacterial DNA-induced immune activation when used at high-enough concentrations [85, 120, 123, 124] . Interestingly, mammalian DNA, in addition to being heavily methylated, also contains telomeric sequences not found in bacterial DNA. Synthetic ODNs containing repetitive telomeric repeats (TTAGGGn) were capable of blocking CpG-DNA induced activation in vitro [86] and, most importantly, reduced morbidity and mortality when administered to lupus prone NZB/NZW mice [125] . Inhibitory action of telomeric repeats heavily depended on the ability of G repeats to form stable secondary structures [86] but, interestingly, purified G tetrad containing aggregates, in contrast to monomers, failed to inhibit CpG-DNA induced IL-6 by human B cells [126] . Similarly to poly-G sequences, ODNs containing repetitive TTAGGG motifs could directly block murine IFN-γ or IL-12 induced STAT (signal transducer and activator of transcription) phosphorylation, T-bet induction, and T-helper-1 differentiation [121] .
Our major contribution to the field was to demonstrate the existence of short (10-15 bases long) single-stranded DNA sequences that could inhibit the action of stimulatory CpG sequences with high potency (50% inhibition at 10-20 nmol/l concentrations) [127] [128] [129] [130] . We determined that the exact specificity requirements were located in three regions of the sequence [129, 131] . The optimal sequence contains a 5′ CCT, a C-free linker four to five bases long, and a GGG(G) tail, with the order also being critical [129, 131] . Despite the differing sequence preferences for stimulation between cell types and species, the most potent inhibitory sequences for all human and mouse cell types tested were as follows: TCCTGGAGGGGAAGT (2114); TCCTGGCGGGGAAGT (2088); TCCTGGATGGGAAGT (4024); and CCTGGA-TGGGAAGT (4084). All of these were made with the nuclease-resistant PS backbones. Natural PO versions of the most potent inhibitory oligodeoxynucleotides (INH-ODNs) were still inhibitory, although with about 10-to 100-fold lower potency, in contrast to simple poly-G strings, which were noninhibitory [85] . We now call these inhibitors class B INHODNs (B for 'broadly reactive'), because they block TLR9-mediated activation in all TLR9-expressing cells. [132] . Interestingly, some INH-ODNs were capable of blocking both TLR7-and TLR9-induced activation of autoreactive B cells [93] , whereas the others exhibited preferential specificity for the TLR7 pathway [114] .
A new classification
We propose a model classifying cell subsets by the structures they require for CpG stimulation. The first category (type I TLR9-expressing cells) includes myeloid and pDCs, macrophages and MZ-B cells in mice, and pDCs, MZ-B cells and memory B cells in humans, which can respond directly and without priming to both single-stranded and more complex CpG-DNA structures.
In contrast, the second category (type II TLR9-expressing cells) includes primarily follicular B cells in mice (and possibly colon epithelial cells and naïve B cells in humans) that directly respond to single stranded CpG-DNA, whereas they require additional co-signals to gain responsiveness to more complex CpG-DNA. We also propose that the primary abnormality in lupus occurs in type I cells, which develop a lower threshold for responding to self CpG-DNA (or self-RNP), ultimately leading to progression from low-specificity autoimmune reactivity to high-specificity pathogenic autoimmunity, or disease. We next offer the concept of class R INH-ODNs (R for 'restricted'), which specifically and primarily target type I responsive cells but spare type II TLR9-expressing cells. We discovered that when our initial INH-ODNs were modified to include partial or complete palindromic sequences, G-rich ends, 3′ or 5′ overhangs, or other modifications that result in the formation of more complex secondary and tertiary structures (Table 1) , these INH-ODNs were much less potent in follicular B cells, which are type II TLR9-expressing cells. Because all type R INH-ODNs have at least partial dsDNA structure, they will be preferentially recognized by dsDNAreactive, and therefore lupus-pathogenic, B cells. Furthermore, these class R INH-ODNs will be delivered to TLR9-containing endosomes in B cells, not by less efficient passive uptake but, rather, via highly efficient uptake through the B cell antigen receptors specific for dsDNA. Therefore, we propose that class R INH-ODNs might specifically target autoreactive B cells and thereby also inhibit pDC-mediated IFN-α production. This may be advantageous over the existing protocols that nonselectively suppress all lupus B cells [133, 134] . Eventually, this may result in more lupus friendly therapy, offering new hopes for lupus patients.
Conclusion
TLR signaling plays an important role in the pathogenesis of SLE. Circulating DNA/anti-DNA complexes (or RNP/anti-RNP complexes) are capable of inducing proliferation of autoreactive B cells and IFN-α secretion from pDCs. Lupus mice that lack TLR9 do not produce anti-chromatin (dsDNA) antibodies. We propose herein a model in which initial activation of MZ-B cells and pDCs with self-derived hypomethylated DNA triggers a chain of events ultimately leading to systemic autoimmune disease. TLR9-induced activation can be specifically and potently blocked with INH-ODNs when used at low nanomolar concentrations. Based on the ability of certain INH-ODNs to block selectively TLR9-induced activation of a subset of TLR9-expressing cells (e.g. MZ-B cells and pDCs) but spare activation of other TLR9 + cells (e.g. follicular B cells), we now classify INH-ODN into two categories: class B (broadly reactive) and class R (restricted reactivity). We therefore see a possible therapeutic role for class R INH-ODNs as a means to suppress disease-specific autoimmune B cell responses, while sparing non-autoimmune and protective humoral and T-cell-mediated antimicrobial immune responses. Moreover, because some INH-ODNs share specificity for both TLR7 and TLR9 pathways, whereas others preferentially block TLR7-mediated activation, intelligible application of these small molecular compounds may result in better treatment protocols for different clinical subsets of SLE patients.
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